不同剂量他克莫司治疗难治性重症肌无力效果观察

目的 探讨分析不同剂量他克莫司治疗难治性重症肌无力患者的临床效果.方法 选取2014年12月～2019年12月收治的72例难治性重症肌无力患者随机分为小剂量组(2 mg/d他克莫司)和大剂量组(3 mg/d他克莫司),比较两组临床疗效,治疗前、治疗后2、4、12周进行QMG、ADL评分及不良反应发生率分析.结果 小剂量...

Observation on the effect of different doses of tacrolimus on patients with refractory myasthenia gravis

Objective To explore and analyze the effects of different doses of tacrolimus in the treatment of patients with refractory myasthenia gravis.Methods 72 patients with refractory myasthenia gravis admitted from December 2014 to December 2019 were randomly divided into small dose groups (2 mg/d tacrolimus) and high-dose group (3 mg/d tacrolimus),compare the clinical efficacy of the two groups,QMG,ADL score and incidence of adverse reactions before treatment,2,4,12 weeks after treatment.Results The total effective rates of clinical efficacy in the low-dose group and the high-dose group were 88.89% and 91.67%,respectively.There was no statistically significant difference(P＞0.05),and there was no significant difference in QMG and ADL scores between the two groups before treatment(P＞0.05) The QMG score of the low-dose group showed a downward trend after 4 weeks of treatment,and the ADL score showed an upward trend,and the differences were statistically significant(P＜0.05).The QMG score of the high-dose group showed a downward trend after 2 weeks of treatment and the ADL score showed an upward trend The difference was statistically significant(P＜0.05).After 2 weeks of treatment,the QMG score of the high-dose group was significantly lower in the lower-dose group and the ADL score was significantly higher in the lower-dose group.The difference was statistically significant(P＜0.05),but Two groups of QMG for 4 and 12 weeks of treatment There was no significant difference in ADL score(P＞0.05).The incidence of adverse reactions in the low-dose group was 2.78% and 22.23% in the larger-dose group was significantly reduced.The differences were statistically significant(P＜0.05).Conclusion Low-dose tacrolimus can significantly improve the clinical symptoms of patients with refractory myasthenia gravis after 4 weeks.After 12 weeks,the clinical efficacy is equivalent to that of the high-dose group,and the incidence of adverse reactions is significantly reduced.It is worthy of clinical promotion.